Early observations and pilot data that first suggested a new direction
PIVENS randomized 247 adults with NASH and without diabetes to pioglitazone 30 mg daily, vitamin E 800 IU daily, or placebo for 96 weeks. Vitamin E improved NASH histology in 43% versus 19% with placebo (P=0.001). Pioglitazone achieved improvement in 34% versus 19% (P=0.04), which did not meet the prespecified significance threshold of P<0.025. Neither agent significantly improved fibrosis scores.
Landmark RCTs and pivotal trials that established the evidence base
MAESTRO-NASH evaluated resmetirom in biopsy-confirmed NASH with F1B–F3 fibrosis. In the 966-patient primary analysis population, 100 mg daily achieved NASH resolution without fibrosis worsening in 29.9% versus 9.7% with placebo, and at least one-stage fibrosis improvement without NAFLD-activity-score worsening in 25.9% versus 14.2%, at week 52 (both P<.001). In March 2024, US accelerated approval covered adults with noncirrhotic NASH and F2–F3 fibrosis, alongside diet and exercise; this indication is narrower than the trial’s fibrosis eligibility.
Follow-up studies, subgroup analyses, and real-world validation
The 72-week phase 2 trial randomized 320 patients; its primary and confirmatory histological endpoints were analyzed only in the 230 with F2 or F3 fibrosis. Semaglutide 0.4 mg daily achieved NASH resolution without fibrosis worsening in 59% versus 17% with placebo (P<.001), but fibrosis improvement did not differ significantly (43% versus 33%, P=.48). Mean weight loss was 13% versus 1%. Separately, a 2023 multisociety consensus adopted MASLD in place of NAFLD, addressing exclusionary terminology and stigma and requiring at least one cardiometabolic risk factor.
Integration into clinical practice guidelines and recommendations
EASL 2024 weight-loss targets in MASLD with overweight are ≥5% for liver fat, 7–10% for inflammation and ≥10% for fibrosis. AASLD 2023 considers vitamin E in selected patients without diabetes; EASL 2024 does not recommend it as MASH-targeted therapy. Resmetirom use follows local approval and labeling in noncirrhotic MASH with significant fibrosis. GLP-1 RAs should be used for their respective diabetes or obesity indications; the cited guidance does not establish them as MASH-targeted antifibrotic therapy.
AASLD
Consider vitamin E in select nondiabetic NASH; semaglutide for its approved T2D/obesity indications, without proven antifibrotic benefit.
EASL
Locally approved resmetirom for noncirrhotic MASH ≥F2; GLP-1 RAs for their respective T2D/obesity indications.
Now
Current standard of care and ongoing research directions
Resmetirom received US accelerated approval in March 2024 for adults with noncirrhotic NASH and F2–F3 fibrosis, with diet and exercise. The phase 2 semaglutide trial improved NASH resolution but did not significantly improve fibrosis. Open questions include the roles of GLP-1 RAs, FGF21 analogues, PPAR agonists and combination approaches, patient selection and non-invasive biomarkers for treatment monitoring.
Resmetirom (Rezdiffra) is an oral, liver-directed thyroid hormone receptor-beta agonist. In MAESTRO-NASH, 100 mg daily produced NASH resolution without fibrosis worsening in 29.9% versus 9.7% with placebo, and fibrosis improvement without activity-score worsening in 25.9% versus 14.2%, at week 52. US accelerated approval in March 2024 covered adults with noncirrhotic NASH and F2–F3 fibrosis, alongside diet and exercise.
What is the difference between NAFLD/NASH and MASLD/MASH?+
The 2023 multisociety consensus replaced NAFLD with metabolic dysfunction-associated steatotic liver disease (MASLD), requiring at least one of five cardiometabolic risk factors. MASH denotes metabolic dysfunction-associated steatohepatitis, previously NASH. The change addressed exclusionary and potentially stigmatizing terminology. Alcohol-related overlap is handled separately through MetALD rather than implying that alcohol assessment is unnecessary.